PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Depemokimab→

Depemokimab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2243274-14-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Long-acting humanised monoclonal antibodyinterleukin-5 (IL-5) antagonist
Mechanism of action
Binds IL-5 with high affinity and prevents IL-5 from interacting with its receptor on eosinophils, reducing eosinophil maturation, survival and inflammatory activity. Its extended duration supports dosing every six months.
Indications / reported uses
  • Add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adults and paediatric patients aged 12 years and older under the US FDA indication; not for acute bronchospasm or status asthmaticus
  • Add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults under the EMA/Australian product indications where systemic corticosteroids and/or surgery have not provided adequate control

Sources: NLM DailyMed — EXDENSUR (depemokimab-ulaa), label updated 10 June 2026 · EMA EPAR — Exdensur, EU authorisation 12 February 2026 · TGA — Exdensur Australian Prescription Medicine Decision Summary, 12 August 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Depemokimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Depemokimab Permitted Daily Exposure (PDE) report (the Depemokimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Depemokimab Occupational Exposure Limit (OEL) report (the Depemokimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.